ClinicalTrials.gg
RecruitingNCT07401316Updated Jun 15, 2026

Circulating Tumor DNA in Stage I, II, and III Germ-Cell Tumors

An interventional study of Whole blood for ctDNA in Germ Cell Cancer Metastatic, sponsored by Indiana University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by Indiana University · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
130
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 94 studies in Neoplasms, Germ Cell and Embryonal with a site in United States — 25 open to participants now, 36 under way, 3 of them phase 3. Neoplasms, Germ Cell and Embryonal · United States.

Planned enrollment
12th of 81
130 · median 36
Started
2026
with 4 others
No phase
7 of 94
2 open now
Primary completion
2032-12
later than 33 of 35 live
Registered
91st of 94
by date
Lead sponsor
4 of 94
Indiana University

Among the 94 studies in Neoplasms, Germ Cell and Embryonal with a site in United States, this one is the 12th largest by planned enrollment of the 81 interventional ones that give a count, is one of 5 that started in 2026, is one of 7 with no phase, reaches primary completion later than 33 of the 35 other live ones, and was the 91st registered.

Neoplasms, Germ Cell and Embryonal

167 studies on the registry are indexed under Neoplasms, Germ Cell and Embryonal; 49 are open to participants now.

Browse Neoplasms, Germ Cell and Embryonal studies →

Open to participants now

25 of the 94 studies in Neoplasms, Germ Cell and Embryonal with a site in United States are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 40 Neoplasms, Germ Cell and Embryonal studies recruiting now, 20 (50%) set no upper age limit and 16 (40%) stop at 75 or younger; 22 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies in Neoplasms, Germ Cell and Embryonal with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the utility of ctDNA detection in patients with high-risk stage I, stage II, and stage III germ cell tumor disease to develop a tool for post-treatment cancer cell detection.

Read the detailed description

This is a specimen collection study where patients with high-risk stage I germ cell tumor, clinical stage II germ cell tumor, and clinical stage III germ cell tumor will be evaluated for ctDNA.

03

Conditions studied

  • Germ Cell Cancer Metastatic

Keywords

  • ctDNA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥ 18 years old at the time of
  2. Ability to provide written informed consent and HIPAA authorization
  3. Subjects must have histologically or serologically confirmed seminomatous or non seminomatous germ cell tumor. Non-seminoma includes embryonal carcinoma, choriocarcinoma, yolk sac tumor, or teratoma.

    Note: Cohort I is for high-risk clinical stage I disease (high risk will be defined as per enrolling investigator discretion). Cohort II is for clinical stage II. Cohort III is for clinical stage III or IS.

  4. for germ-cell tumor diagnosis available

Exclusion criteria

Exclusion Criteria:

  1. Concurrent disease or condition that would make the subject inappropriate for study participation
  2. Any serious medical disorder that would interfere with the subject's safety
  3. Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of per treating physician coverage.
  4. Patient is being tested for minimal residual disease with other experimental platforms
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
130 participants (estimated)

Study arms

  • Experimental
    Cohort I - High Risk Clinical stage I

    50 subjects will be enrolled with high-risk stage I seminomatous or non-seminomatous germ cell tumors. In these patients, ctDNA will be collected post-orchiectomy prior to initiation of surveillance and every 4 months during surveillance for up to 2 years.

    Diagnostic Test: Whole blood for ctDNA

  • Experimental
    Cohort II- Clinical stage II

    30 patients will be enrolled with clinical Stage II seminomatous or non-seminomatous germ cell tumor who are planning to undergo primary resection with RPLND. In these patients, ctDNA will be collected prior to surgery and every 4 months after surgery for up to 2 years.

    Diagnostic Test: Whole blood for ctDNA

  • Experimental
    Cohort III- Clinical stage III

    50 patients will be enrolled with clinical Stage III (or IS) seminomatous or non-seminomatous germ cell tumor who are planning to undergo first-line chemotherapy. In these patients, ctDNA will be collected prior to chemotherapy, at cycle 2 day 1, within 28 days of starting last cycle of chemotherapy, and every 4 months after completing chemotherapy.

    Diagnostic Test: Whole blood for ctDNA

Interventions

  • Diagnostic testWhole blood for ctDNA

    Whole blood for ctDNA

06

What researchers measure

Primary outcomes

  1. Positive predictive value (PPV) of circulating tumor DNA in Cohort I

    PPV will be calculated as the number of true positives divided by the total number of positive tests in patients with high-risk stage I germ cell tumor.

    Time frame: At screening and every 4 months up to 2 years

  2. Positive predictive value (PPV) of circulating tumor DNA in Cohort II

    PPV will be calculated as the number of true positives divided by the total number of positive tests in the node dissection patients with clinical stage II germ cell tumor.

    Time frame: At screening and every 4 months up to 2 years

  3. Positive predictive value (PPV) of circulating tumor DNA in Cohort III

    PPV will be calculated as the number of true positives divided by the total number of positive tests in the first-line chemotherapy patients with clinical stage III germ cell tumor.

    Time frame: At screening and every 4 months up to 2 years

Secondary outcomes

  1. Negative predictive value (NPV) of circulating tumor DNA in Cohort I

    NPV will be calculated as the number of true negatives divided by the total number of negative tests in patients with high-risk stage I germ cell tumor.

    Time frame: At screening and every 4 months up to 2 years

  2. Negative predictive value (NPV) of circulating tumor DNA in Cohort II

    NPV will be calculated as the number of true negatives divided by the total number of negative tests in the node dissection patients with clinical stage II germ cell tumor.

    Time frame: At screening and every 4 months up to 2 years

  3. Negative predictive value (NPV) of circulating tumor DNA in Cohort III

    NPV will be calculated as the number of true positives divided by the total number of positive tests in the first-line chemotherapy patients with clinical stage III germ cell tumor.

    Time frame: At screening and every 4 months up to 2 years

  4. Post-node dissection circulating tumor DNA bioassay

    Means/stds of ctDNA in both the relapsed and non-relapsed patients in Cohort II.

    Time frame: At screening and every 4 months up to 2 years

  5. Post-node dissection clearance rate of ctDNA

    The clearance rate of ctDNA in the node dissection patients in Cohort II.

    Time frame: At screening and every 4 months up to 2 years

07

Study locations

1 of 1 sites recruiting
  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center
    Indianapolis, Indiana 46202, United States
    Recruiting
    • Marietta Moore, RN · Contactkaelmoor@iu.edu · 317-274-7477
    • Nabil Adra, MD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Dec 2032, 78 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2026
First posted
Feb 10, 2026
StartActual
Jun 3, 2026
Primary completionEst.
Dec 2032
CompletionEst.
Dec 2032
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07401316
Lead sponsor
Indiana University
Collaborators
Natera, Inc.
Responsible party
Nabil Adra (Associate Professor of Clinical Medicine, Indiana University) — Principal investigator
First posted
Feb 10, 2026
Start date
Jun 3, 2026
Primary completion
Dec 2032 (estimated)
Completion
Dec 2032 (estimated)
Last update
Jun 15, 2026

Study contacts

Marietta Moore, RN
Contact
marlmoor@iu.edu
317-274-7477
Nabil Adra, MD
principal investigator · Indiana University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion